About
Gerhard Koenig, PhD, is a biotech executive and neuroscience drug-development veteran who became CEO of Augustine Therapeutics in January 2025 after serving on its board and as executive chairman. He previously co-founded and led Arkuda Therapeutics, whose lysosomal-function-enhancer portfolio was acquired by Johnson & Johnson in January 2025. Earlier roles included CEO of Quartet Medicine, CSO/SVP at FORUM Pharmaceuticals, senior R&D roles at Bayer, and a vice president role at Fidelity Biosciences Group (now F' Prime Capital).
Areas of interest
biotechneuroscienceneurodegenerationalzheimers diseaseparkinsons diseaseneuromuscular diseasecardiometabolic diseasedrug development